Background & Aims: Simeprevir is an oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of chronic HCV infection. Baseline NS3 polymorphisms in all patients and emerging mutations in patients who failed to achieve sustained virologic response (SVR) with simeprevir plus peginterferon/ribavirin (PR) in Phase IIb/III studies are described. Methods: Baseline sequencing data were available for 2007 genotype 1 (GT1)-infected patients. Post-baseline data were available for 197/245 simeprevir-treated patients who did not achieve SVR. In vitro simeprevir susceptibility was assessed in a transient replicon assay as site-directed mutants or in chimeric replicons with patient-derived NS3 protease sequences. Results: Baseline NS3 polymorphisms at positions associated with reduced in vitro susceptibility to simeprevir (43, 80, 122, 155, 156, and/or 168; EC 50 fold change >2.0) were uncommon (1.3% [26/2007]), with the exception of Q80K, which confers $10-fold reduction in simeprevir activity in vitro (13.7% [274/2007]; GT1a 29.5% [269/911], GT1b 0.5% [5/1096]). Baseline Q80K had minor effect on initial response to simeprevir/PR, but resulted in lower SVR rates. Overall, 91.4% of simeprevir-treated patients [180/197] without SVR had emerging mutations at NS3 positions 80, 122, 155, and/or 168 at failure (mainly R155K in GT1a with and without Q80K, and D168V in GT1b), conferring high-level resistance in vitro (EC 50 fold change >50). Emerging mutations were no longer detectable by population sequencing at study end in 50% [90/180] of patients (median follow-up 28.4 weeks). Conclusions: Simeprevir treatment failure was usually associated with emerging high-level resistance mutations, which became undetectable over time in half of the patients. Ó 2014 European Association for the Study of the Liver. Published by Elsevier B.V.
Introduction
Hepatitis C virus (HCV) infection represents a major public health concern, with approximately 150 million individuals infected worldwide and 3-4 million new infections annually [1] . HCV infection is the leading cause of liver cirrhosis, hepatocellular carcinoma, and liver transplantation.
Simeprevir (TMC435) is a recently approved, one-pill, once-daily (QD), oral HCV NS3/4A protease inhibitor. The anti-HCV activity of simeprevir plus peginterferon/ribavirin (PR) in patients with chronic HCV genotype 1 (GT1) infection has been demonstrated in five multicenter, Phase IIb/III studies [2] [3] [4] [5] [6] . In Phase IIb studies (PILLAR and ASPIRE), sustained virologic response (SVR) rates in patients treated with simeprevir/PR were 81-86% in treatment-naïve patients [2] , 77-89% in prior relapsers, and 41-86% in prior null and partial responders [3] . In Phase III studies (QUEST-1, QUEST-2, and PROMISE), SVR rates were significantly higher in patients who received simeprevir/PR compared with PR control (80% vs. 50% in treatment-naïve patients and 79% vs. 37% in prior relapsers) [4] [5] [6] . In these studies, approximately 90% of patients met response-guided treatment criteria and were eligible for 24 weeks of PR treatment; SVR rates in these patients ranged from 83% to 91%. Moreover, simeprevir is generally well tolerated ($3800 patients treated in clinical trials to date).
Treatment failure in HCV-infected patients receiving a direct-acting antiviral agent (DAA)-based regimen has been associated with the emergence of resistance mutations in the target region of these agents [7, 8] . In addition, naturally occurring amino acid substitutions in NS3 -also referred to as polymorphisms -that can reduce the antiviral activity of DAAs have been reported [9] . In this paper, we describe NS3 baseline polymorphisms in HCV GT1-infected patients enrolled in the simeprevir Phase IIb/III studies. We also describe the effect of baseline NS3 Q80K polymorphism on antiviral activity and efficacy of simeprevir/PR, and characterize emerging mutations in patients who received simeprevir/PR and did not achieve SVR.
Patients and methods
Study design NS3 sequence data were analyzed from five Phase IIb/III studies of simeprevir/PR (PILLAR, ASPIRE, QUEST-1, QUEST-2, and PROMISE) ( Supplementary Table 1 ) [2] [3] [4] [5] [6] . The prevalence of baseline NS3 polymorphisms was analyzed in all patients enrolled in these studies (N = 2026 in total; n = 2007 patients with sequence data). Paired baseline and post-baseline sequences at the time of failure were available from 197 patients treated with 150 mg simeprevir/PR who did not achieve SVR. The effect of the NS3 Q80K polymorphism on outcome of treatment with simeprevir 150 mg QD in combination with PR therapy was assessed by study and in a pooled analysis of the two Phase III studies in treatment-naïve patients (QUEST-1 and QUEST-2; n = 515 patients treated with simeprevir/PR and sequencing data available) [10] .
All studies were conducted in full compliance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent before participating in any study-related activity.
HCV NS3/4A sequence analysis and subtype determination
HCV geno/subtypes were determined at screening by Trugene or Versant LiPA v2 assay (Siemens Healthcare Diagnostics, IL, USA). HCV GT subtypes were also determined at baseline by sequencing a 329 bp region within NS5B followed by basic local alignment search tool (BLAST) analysis. The results of the NS5B-based assay were used for efficacy and virology analyses. According to the NS5B-based assay, 15 of the 2026 patients enrolled in the five Phase IIb/III studies had non-GT1a/1b subtypes (GT1: n = 4; GT1e: n = 4; GT1d: n = 2; GT1 g, 1i, 1l, 6e, and 6p: each n = 1). Data for patients with non-GT1a/1b subtypes were analyzed together with that for GT1a patients.
NS3/4A sequencing was performed at baseline for all patients and post-baseline for simeprevir/PR-treated patients who did not achieve SVR for any reason. Samples from patients not achieving SVR were selected for sequencing based on the timepoint of failure, availability of samples until end of study (EOS), and the sensitivity of the sequencing assay. The HCV NS3/4A region or the NS3 protease domain was sequenced using standard Sanger population sequencing [11] .
Polymorphisms were defined as amino acid changes from the H77 (GenBank accession number AF009606) or the HCV Con1 (GenBank accession number AJ238799) reference sequences for HCV GT1a/other and GT1b, respectively. Emerging mutations were defined as amino acid changes from patient-specific baseline sequences.
Two lists of NS3 amino acid positions of interest were defined to guide the analyses. The first list comprised six NS3 amino acid positions: 43, 80, 122, 155, 156, and 168; specific amino acid changes at one or more of these positions are known to confer reduced susceptibility to simeprevir in vitro [12, 13] . The second list also included NS3 positions that have been associated with resistance to other HCV NS3/4A protease inhibitors or that were considered of interest based on observations in in vitro or in vivo studies with simeprevir [12] [13] [14] [15] . This list comprised 18 NS3 amino acid positions: 36, 41, 43, 54, 55, 80, 107, 122, 132, 138, 155, 156, 158, 168, 169, 170, 174, and 175. In addition, statistical analyses were performed to identify emerging mutations associated with simeprevir treatment failure (Supplementary Table 2 ).
Phenotypic characterization using a transient replicon assay
Mutations were engineered in a GT1b or GT1a replicon; for the chimeric replicon assay, sequences of the NS3 protease domain (aa7-192) derived from patient isolates were introduced into a GT1b replicon backbone generating chimeric replicons. Antiviral activity of simeprevir against the mutants or chimeric replicons was assessed in a transient replicon assay using luciferase read-out, quantified by the half maximal effective concentration (EC 50 ) values, and compared with that of a reference GT1b wild-type HCV replicon, as described earlier. Fold changes in EC 50 were calculated [12] . Patients n (%) Any polymorphism with SMV FC ≤2.0 Q80G Q80L Q80N S122C S122G S122N S122T S122N/T Q80L + S122G Q80L + S122N - 
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Results
Baseline NS3 polymorphisms
With the exception of the low-level resistance polymorphism Q80K, baseline NS3 polymorphisms associated with reduced in vitro susceptibility to simeprevir (at positions 43, 80, 122, 155, 156, and 168; fold change in EC 50 value >2.0 as site-directed mutant in transient replicon assay) were generally uncommon (1.3%; 26/2007) ( Fig. 1 ). Among patients treated with 150 mg simeprevir/PR in the Phase IIb/III treatment-naïve and -experienced studies, 6/9 patients with Q80R, 3/4 with R155K, and 3/6 with D168E polymorphisms achieved SVR. Given the low prevalence of these baseline polymorphisms, no conclusion can be made concerning their possible impact on the outcome of simeprevir/PR therapy. NS3 polymorphisms at any of the six positions of interest that did not reduce simeprevir activity in vitro (fold change in EC 50 value 62.0) were observed in 13.9% of patients ( Fig. 1 ). Consistent with the in vitro activity of simeprevir against these mutants, no impact on treatment outcome was observed (data not shown). Of note, no polymorphisms were observed at NS3 amino acid positions 43 and 156.
Overall, the NS3 Q80K polymorphism was present in 13.7% of patients (274/2007): 29.5% (269/911) of GT1a and 0.5% (5/1096) of GT1b patients. Large regional differences in Q80K polymorphism prevalence were noted with the highest prevalence in North America (Table 1) .
A Q80K amino acid substitution reduced simeprevir activity in vitro, with a 7.7-and 9.3-fold change in EC 50 when tested as site-directed mutant in GT1b and GT1a replicon backbones, respectively ( Fig. 1 ). Baseline HCV GT1a isolates carrying Q80K displayed a median 11-fold change in simeprevir EC 50 (n = 33) (data not shown). Patients with Q80K at baseline experienced a rapid and pronounced initial decline in HCV RNA from baseline during treatment with simeprevir/PR in Phase IIb/III studies, consistent with the limited effect of Q80K on simeprevir activity observed in vitro. In the pooled, treatment-naïve, Phase III studies (QUEST-1/QUEST-2) [10] , treatment with simeprevir/PR resulted in a mean change in HCV RNA from baseline to week 1 of À4.1 and À4.6 log 10 IU/ml in GT1a patients with and without Q80K, respectively, compared with À1.1 log 10 IU/ml in patients treated with placebo/PR ( Fig. 2 ). However, following the initial decline in HCV RNA levels, treatment failure occurred more frequently in simeprevir/PR-treated GT1a patients with baseline Q80K than in those without this polymorphism. On-treatment failure occurred in 19.0% (16/84) vs. 7.9% (13/165) of HCV GT1a patients with and without Q80K, respectively, and viral relapse in 22.2% (14/63) vs. 6.0% (9/149), respectively. Almost all patients with baseline Q80K who failed simeprevir had emerging mutations that, in combination with Q80K, conferred high-level resistance ( Table 2 ).
The SVR rates achieved in HCV GT1a patients with baseline Q80K were numerically higher in the simeprevir group than in the placebo/PR group in the pooled QUEST- Table 2) .
Although the frequency of emerging mutations in patients with treatment failure was similar for GT1a and GT1b, different mutations emerged (Table 2 ). An emerging mutation at time of failure was observed in 61/63 GT1a patients (96.8%) without baseline Q80K. The majority of these patients had emerging R155K alone (25 patients, 41.0%) or R155K in combination with other mutations at NS3 positions 80, 122, and/or 168 (22 patients, 36.1%). In 49/53 GT1a patients (92.5%) with baseline Q80K, an emerging mutation at time of failure was observed. The majority of these patients (41 patients, 83.7%) had an Of note, emerging R155K was not observed in patients with GT1b, while some mutations at position 168 were also observed in patients with GT1a. Considering the 18 NS3 positions of interest, two additional patients had emerging mutations (I170T in two GT1a patients with baseline Q80K). I170T (15-fold change in EC 50 values as single mutant in GT1a replicon) was also observed in combination with R155K in three GT1a patients. In addition, in 11 of 197 patients with treatment failure and sequence data available, mutations at NS3 positions 36 (V36M, n = 1), 107 (V107I, n = 2), 132 (I132L, n = 3), 170 (V170I, n = 1), 174 (S or N174F, or S, n = 4), and V132L+N174G (n = 1) were observed in combination with emerging mutations at positions 80, 155, and/or 168. With the exception of I132L (4.5-fold change in EC 50 values), none of the mutations reduced simeprevir activity (62.0-fold change in EC 50 values) when tested as a single mutant in a GT1b or 1a replicon backbone (data not shown). No emerging mutations at the time of failure were observed at NS3 positions 41, 43, 54, 55, 138, 156, 158, 169, and 175.
Emerging mutations in the NS3 protease domain outside of the 18 positions of interest were rarely observed (i.e. none in more than three patients [1.5%] with failure) and almost always in combination with mutations at positions of interest.
Statistical analyses comparing sequence data from simeprevir/PR-treated patients not achieving SVR against the respective baseline samples (paired Liddell test) or a reference sequence set (unpaired Fisher exact test) identified emerging mutations Q80R, S122R, R155K, D168A, D168E, D168V, and V/I170T as being significantly associated with simeprevir/PR treatment failure (Supplementary Table 2 ).
Of note, although proportions of patients not achieving SVR differed by prior response to peginterferon treatment, the proportions of patients with emerging mutations and type of emerging mutations among the patients failing treatment were similar irrespective of prior treatment history.
Phenotypic characterization
NS3 sequences derived from clinical isolates obtained at baseline and time of failure were introduced in a chimeric GT1b replicon, and susceptibility to simeprevir was assessed. Among the tested baseline isolates, those carrying a Q80K or R155K amino acid substitution showed approximately 10-and 90-fold reduction in simeprevir activity compared with the reference wild-type replicon, respectively (Fig. 3) . Most of the remaining baseline isolates tested were fully susceptible to simeprevir in vitro (62.0-fold change in EC 50 ). Clinical isolates obtained at time of failure generally showed decreased susceptibility to simeprevir (median fold change in EC 50 , 370 [range: 0.2-3110] vs. the reference wild-type GT1b replicon). All isolates carrying emerging mutations at positions 80, 122, 155, and/or 168 at time of failure showed an increase in EC 50 values vs. their respective baseline Q80R + S122A or T + D168E (n = 2) R155Q + D168V (n = 2) R155Q + D168A (n = 1) S122I or T + D168V or F (n = 2) a May include some patients with GT non-1a/b subtypes.
GT, genotype; PR, peginterferon/ribavirin; SVR, sustained virologic response.
isolates (median fold change P62 vs. the reference wild-type GT1b replicon). Of the isolates analyzed, 6 failure isolates did not carry emerging mutations: one carried an R155K and two a Q80K amino acid substitution (all GT1a), which were already present at baseline. No reduction was observed in susceptibility to simeprevir between baseline and time of failure, consistent with the absence of emerging mutations (Fig. 3 ).
Persistence of emerging mutations
Patients enrolled in the simeprevir Phase IIb/III studies were followed for 72 weeks after treatment initiation, irrespective of treatment duration or outcome. The persistence of viral variants after treatment failure until the last available timepoint (EOS) was investigated in simeprevir/PR-treated patients with failure. Sequences at EOS in patients with treatment failure were compared against the sequences available at time of failure and baseline. Median time of the EOS visit after the time of failure was 28.4 weeks (range: 0-69.9 weeks). For 90/180 patients (50.0%) with emerging mutations at time of failure, emerging mutations were no longer observed at EOS with population sequencing (GT1a: 46/100 [41.8%] and GT1b: 44/70 [62.9%]).
Kaplan-Meier analyses were performed to evaluate the persistence of emerging mutations over time. Median time until the emerging mutations became undetectable using population sequencing was shorter in patients infected with HCV GT1b (24 weeks; range: 19.6-36.1 weeks) compared with GT1a (36 weeks; range: 31.7-40.9 weeks) ( Fig. 4A) . Median time until emerging mutations became undetectable was shorter in patients with D168V (mainly GT1b [17 weeks; range: 12.1-20.1 weeks]) and in GT1a patients with emerging R155K who had baseline Q80K (32 weeks; range: 30.1-35.9 weeks) compared with GT1a patients who had emerging R155K without baseline Q80K (64 weeks; range: 40.1-70.0 weeks) (Fig. 4B ).
Discussion
Analyses of the HCV NS3/4A sequence at baseline in patients enrolled in the simeprevir Phase IIb/III studies identified naturally occurring sequence polymorphisms. However, with the exception of Q80K, baseline polymorphisms reducing the in vitro activity of simeprevir were uncommon. Overall, the Q80K polymorphism was present in 13.7% of GT1 patients at baseline and was almost exclusively found with GT1a (29.5%). The prevalence of Q80K polymorphism within GT1a differs by region. Recent studies suggest that two clades of GT1a circulate worldwide, one carrying a lysine (K) with a high prevalence at position 80 and the other carrying a glutamine (Q) [16, 17] ; for reasons that are not fully understood, the K80 clade disseminated more effectively in North America than the Q80 clade. In addition, the ratio of GT1a to GT1b also differs across regions. For example, GT1b is almost exclusively present in the HCV GT1 population of large parts of Eastern Europe and Asia, while in other regions, such as North America, GT1a is more prevalent than GT1b. The combination of the high prevalence of GT1a and the higher prevalence of Q80K within GT1a resulted in the highest Q80K prevalence in the GT1 population of North America (34.4%), while the GT1 Q80K prevalence in Europe was 6.1%.
The Q80K polymorphism is located in the S2 binding site of NS3 and stabilizes the R155 residue, which is relocated during simeprevir binding to form the extended S2 subsite. Consistent with these structural features, Q80K as a single mutation in GT1a backbone reduced the in vitro activity of simeprevir by 9.3-fold, but when Q80K was present in combination with R155K (88-fold change in EC 50 value of R155K alone in GT1a backbone), simeprevir activity was reduced by $2000-fold. When simeprevir was given at lower doses, such as 25 mg or 75 mg, the presence of a Q80K variant at baseline reduced the decline in HCV RNA during the first few days of treatment, a parameter that is an indicator of the intrinsic potency of the drug on baseline virus without the confounding effects of the host factors [2, 18] . In contrast, in patients receiving simeprevir 150 mg, the initial reduction in HCV RNA was minimally affected by the presence of Q80K.
The initial antiviral activity in simeprevir/PR-treated HCV GT1a-infected patients with Q80K at baseline was followed by higher on-treatment failure and relapse rates, resulting in lower SVR rates at 12 weeks vs. simeprevir/PR-treated HCV GT1a-infected patients without this polymorphism. This higher rate of failure was accompanied by the emergence of additional mutations (mainly R155K), which in combination with Q80K resulted in high-level resistance to simeprevir that could not be contained by the simeprevir drug levels achieved with the 150 mg dose. Based on this observation, it can be speculated that as a whole, Q80K-containing virus populations might display a lower resistance barrier, therefore facilitating the emergence of resistance mutations if the antiviral activity of the PR component is insufficient to suppress these emerging variants. Of note, SVR rates with simeprevir/PR regimens in patients with Q80K also depended on factors associated with response to PR (e.g. IL28B GT, METAVIR score; Supplementary Table 4 ). In an interferon-free regimen of simeprevir combined with sofosbuvir, high SVR rates at 12 weeks (88%) were achieved in traditionally difficult-to-cure GT1a-infected patients with Q80K [19] .
The majority of patients who failed to respond to simeprevir/PR treatment had emerging mutations at NS3 positions 80, 122, 155, and/or 168. These positions are located in, or close to, the extended S2 binding pocket necessary for simeprevir binding [12, 20] . The mutations present in patients who failed treatment generally conferred high-level resistance to simeprevir in vitro, with >50-fold changes in EC 50 values compared with the wild-type reference replicon, with the majority of patients displaying substantially higher levels of resistance. Additional analyses were performed to assess if mutations beyond the positions of interest were associated with treatment failure; the results confirmed that these were either very infrequent and/or did not affect the in vitro activity of simeprevir [12] .
Emerging mutations differed between patients with GT1a and GT1b infection, but were consistent within each HCV GT subtype. In GT1a patients with Q80K, a single emerging R155K mutation was predominantly observed, while in GT1a patients without Q80K, double or triple mutations of R155K in combination with mutations at position 80, 122, and/or 168 were frequently present. In GT1b patients, R155K was not observed, and treatment failure was typically associated with emerging mutations at position 168, mainly D168V. Of note, only one nucleotide change is needed for an R155K mutation in GT1a, while two are needed for GT1b [21] . Although emerging mutations at position 80 and 122 were observed, only some amino acid substitutions at these positions (Q80K, Q80R, and S122R) reduced the in vitro activity of simeprevir, whereas many other amino acid substitutions, such as Q80L or S122N, had no effect on simeprevir activity [12] .
Mutations that emerged in patients failing to respond to simeprevir treatment became undetectable over time in many patients, based on population sequencing. The follow-up times in the Phase IIb/III studies were limited and differed substantially between patients, which could explain the presence of mutations at the last study-related visit. Kaplan-Meier analyses showed that the median time until an emerging mutation became undetectable was the shortest for GT1b patients with emerging D168V. Among GT1a patients, those with Q80K at baseline and emerging R155K had a shorter time until the emerging R155K mutation became undetectable, compared with patients with emerging R155K who did not have Q80K at baseline, suggesting that emerging variants with R155K in the presence of a Q80K amino acid substitution are less fit in the absence of simeprevir. Of note, patients with Q80K polymorphism at baseline who failed treatment retained this variant throughout the whole study. Similar results showing that emerging NS3 mutations become undetectable over time have been described for other DAAs, such as telaprevir and boceprevir, suggesting lower fitness of these mutant viral strains [8, 22] . Recent studies showed that emerging mutations that became undetectable by population sequencing could also not be detected using more sensitive sequencing technologies [23, 24] . However, in the absence of robust re-treatment data with a protease inhibitor-containing regimen, it is premature to conclude whether the decline in frequency of the emerging mutations is clinically relevant. Importantly, simeprevir resistance mutations remained susceptible to DAAs with other mechanisms of action in vitro, and recent data with sofosbuvir/daclatasvir and sofosbuvir/ledipasvir showed successful re-treatment of patients who failed to respond to protease inhibitor-based treatment with emerging NS3 mutations [25, 26] .
In conclusion, simeprevir in combination with PR results in high SVR rates in HCV treatment-naïve and -experienced patients with HCV GT1 infection. The GT1a NS3 polymorphism Q80K has a modest impact on simeprevir activity in vitro, but might facilitate the emergence of additional mutations in patients treated with simeprevir/PR, especially in those with poor response to interferon, ultimately resulting in lower SVR in these patients when treated with simeprevir/PR. Treatment failure is typically associated with emerging high-level resistance mutations in the NS3 region that decline and become undetectable over time in many patients after treatment is stopped. Recent data suggest that emerging mutations do not preclude successful treatment outcome following subsequent treatment with DAAs with other mechanisms of action.
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